LTX-109
Also known as: LTX 109, LTX‑109, LTX109, Lytix‑109, Lytone
Source LTX-109 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
LTX-109 is a synthetic, cationic antimicrobial peptide under clinical investigation for topical treatment of bacterial skin infections, including those caused by resistant strains.
Mechanism of Action
Rapid, non‑specific disruption of bacterial cell membranes leading to loss of integrity and cell death
Routes of Administration
Goals & Uses
- Treatment of impetigoDermatology / Anti InfectiveModerate
- Skin and soft tissue infection (SSTI) treatmentDermatology / Anti InfectiveLow
- treat bacterial skin infectionsAntimicrobialModerate
- Prevention of MRSA surgical site infectionsInfection PreventionLow
- address antibiotic‑resistant pathogensAntimicrobialModerate
- MRSA nasal decolonizationAnti Infective / DecolonizationModerate
Contraindications
- Application to open wounds or mucous membranes beyond intended siteApplication Site SafetyModerate
- Known hypersensitivity to LTX-109 or excipientsAllergyHigh
- known hypersensitivity to LTX‑109 or formulation componentsAllergyHigh
Adverse Effects
- Local skin irritationDermatologicalCommon
- Erythema at application siteDermatologicUncommon
- Nasal irritationLocal/NasalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Contact dermatitisDermatologicalUncommon
- Application site burning or stingingLocal ReactionCommon
Drug Interactions
- topical antibioticsLow
- Other topical antimicrobials (e.g., mupirocin)Low
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- pediatric use (<12 years)AgeRelative
- Patients with compromised nasal or skin integrityMedical ConditionRelative
- Pregnant or breastfeeding womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical development under EMA guidance.
- United StatesInvestigationalPhase II/III trials ongoing.
- United KingdomInvestigationalUnder UK Medicines and Healthcare products Regulatory Agency review.
Not yet approved in any jurisdiction; currently in Phase II/III clinical trials for topical use.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is LTX-109?
LTX-109 is a synthetic, cationic antimicrobial peptide under clinical investigation for topical treatment of bacterial skin infections, including those caused by resistant strains.
What is LTX-109 used for?
LTX-109 is educationally associated with: Treatment of impetigo, Skin and soft tissue infection (SSTI) treatment, treat bacterial skin infections, Prevention of MRSA surgical site infections, address antibiotic‑resistant pathogens, MRSA nasal decolonization. Educational only — not medical advice.
How is LTX-109 administered?
Recorded routes of administration: Nasal, Topical.
What are the potential side effects of LTX-109?
Reported adverse effects include: Local skin irritation, Erythema at application site, Nasal irritation, Headache, Contact dermatitis, Application site burning or stinging. This list is not exhaustive — consult a qualified clinician.
Who should avoid LTX-109?
Recorded contraindications: Application to open wounds or mucous membranes beyond intended site, Known hypersensitivity to LTX-109 or excipients, known hypersensitivity to LTX‑109 or formulation components. Consult a qualified clinician before use.